• Explore /
  • Poster
  • / High intratumoral tryptophan metabolism is a poor predictor of response to pembrolizumab (pembro) in metastatic melanoma (MM): Results from a prospective trial using baseline C11-labeled alpha-methyl tryptophan (C11-AMT) PET imaging for response prediction.

High intratumoral tryptophan metabolism is a poor predictor of response to pembrolizumab (pembro) in metastatic melanoma (MM): Results from a prospective trial using baseline C11-labeled alpha-methyl tryptophan (C11-AMT) PET imaging for response prediction.

Abstract Poster

Authors

null

Jorge D. Oldan

Department of Radiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC

Jorge D. Oldan , David W. Ollila , Ben C. Giglio , Eric Smith , Deeanna M. Bouchard , Marija Ivanovic , Yueh Z. Lee , Frances A. Collichio , Michael O. Meyers , Diana E. Wallack , Amir H. Khandani , Amber Abernathy-Leinwand , Patricia K. Long , Jennifer Ashley Ezzell , Dimitri G. Trembath , Zibo Li , Terence Z. Wong , Stergios J. Moschos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Molecular Diagnostics and Imaging

Clinical Trial Registration Number

NCT03089606

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3556)

DOI

10.1200/JCO.2020.38.15_suppl.3556

Abstract #

3556

Poster Bd #

286

Abstract Disclosures

Similar Posters

First Author: Hussein Abdul-Hassan Tawbi

First Author: Emily Keung

First Author: Abraham C.F. Leung

First Author: Lydia Gaba